Effects of aerobic exercise with or without metformin on plasma incretins in type 2 diabetes

Canadian Journal of Diabetes

Volumn 37, Issue 6, 2013, Pages 375-380

  Eshghi, Saeed Reza Toghi ^a   Bell, Gordon J ^a   Boulé, Normand G ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Glucagon like peptide 1; Glucose dependent insulinotropic polypeptide; Metformin; Physical activity

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INCRETIN; INSULIN; METFORMIN; PLACEBO; ANTIDIABETIC AGENT;

ADULT; AEROBIC EXERCISE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG DOSE INCREASE; FEMALE; GASTROINTESTINAL SYMPTOM; HORMONE BLOOD LEVEL; HUMAN; MALE; MIDDLE AGED; MORNING DOSAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; BLOOD; DIABETES MELLITUS, TYPE 2; KINESIOTHERAPY; MULTIMODALITY CANCER THERAPY;

COMBINED MODALITY THERAPY; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; EXERCISE THERAPY; FEMALE; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED;

EID: 84889565418     PISSN: 14992671     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcjd.2013.07.030     Document Type: Article

References (41)

1. Elrick H., Stimmler L., Hlad C.J., et al. Plasma insulin response to oral and intravenous glucose administration. JClin Endocrinol Metab 1964, 24:1076-1082.
2. Orskov C., Wettergren A., Holst J.J. Biological effects and metabolic rates of glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable. Diabetes 1993, 42:658-661.
3. Dupre J., Ross S.A., Watson D., et al. Stimulation of insulin secretion by gastric inhibitory polypeptide in man. JClin Endocrinol Metab 1973, 37:826-828.
4. Nauck M.A., Homberger E., Siegel E.G., et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. JClin Endocrinol Metab 1986, 63:492-498.
5. Shuster L.T., Go V.L., Rizza R.A., et al. Incretin effect due to increased secretion and decreased clearance of insulin in normal humans. Diabetes 1988, 37:200-203.
6. Toft-Nielsen M.B., Damholt M.B., Madsbad S., et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. JClin Endocrinol Metab 2001, 86:3717-3723.
7. Vilsboll T., Krarup T., Deacon C.F., et al. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001, 50:609-613.
8. Muscelli E., Mari A., Casolaro A., et al. Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes 2008, 57:1340-1348.
9. Clement M., Hanna A., Main A., et al. Pharmacologic management of type 2 diabetes. Can J Diabetes 2013, 37:S61-S68.
10. Drucker D.J., Nauck M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006, 368:1696-1705.
11. Kieffer T.J., McIntosh C.H., Pederson R.A. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 invitro and invivo by dipeptidyl peptidase IV. Endocrinology 1995, 136:3585-3596.
12. Knowler W.C., Barrett-Connor E., Fowler S.E., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. NEngl J Med 2002, 346:393-403.
13. Pi-Sunyer X., Blackburn G., Brancati F.L., et al. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care 2007, 30:1374-1383.
14. Sigal R.J., Colby P., Kenny G.P., et al. Physical activity and diabetes. Can J Diabetes 2013, 37:S40-S44.
15. O'Connor A.M., Pola S., Ward B.M., et al. The gastroenteroinsular response to glucose ingestion during postexercise recovery. Am J Physiol Endocrinol Metab 2006, 290:E1155-E1161.
16. O'Connor A.M., Johnston C.F., Buchanan K.D., et al. Circulating gastrointestinal hormone changes in marathon running. Int J Sports Med 1995, 16:283-287.
17. Solomon T.P., Haus J.M., Kelly K.R., et al. Improved pancreatic beta-cell function in type 2 diabetic patients after lifestyle-induced weight loss is related to glucose-dependent insulinotropic polypeptide. Diabetes Care 2010, 33:1561-1566.
18. Nathan D.M., Buse J.B., Davidson M.B., et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009, 52:17-30.
19. The Use of Medicines in the United States: Review of 2010. IMS Institute for Healthcare Informatics, Parsippany, NJ, 2011.
20. Yasuda N., Inoue T., Nagakura T., et al. Enhanced secretion of glucagon-like peptide 1 by biguanide compounds. Biochem Biophys Res Commun 2002, 298:779-784.
21. Boule N.G., Robert C., Bell G.J., et al. Metformin and exercise in type 2 diabetes: examining treatment modality interactions. Diabetes Care 2011, 34:1469-1474.
22. Vilsboll T., Krarup T., Madsbad S., et al. Defective amplification of the late phaseinsulin response to glucose by GIP in obese type II diabetic patients. Diabetologia 2002, 45:1111-1119.
23. Hare K.J., Knop F.K., Asmar M., et al. Preserved inhibitory potency of GLP-1 on glucagon secretion in type 2 diabetes mellitus. JClin Endocrinol Metab 2009, 94:4679-4687.
24. Meier J.J., Gallwitz B., Siepmann N., et al. Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia. Diabetologia 2003, 46:798-801.
25. Boule N.G., Weisnagel S.J., Lakka T.A., et al. Effects of exercise training on glucose homeostasis: the HERITAGE Family Study. Diabetes Care 2005, 28:108-114.
26. Johnson S.T., Tudor-Locke C., McCargar L.J., et al. Measuring habitual walking speed of people with type 2 diabetes: are they meeting recommendations?. Diabetes Care 2005, 28:1503-1504.
27. Ainsworth B.E., Haskell W.L., Herrmann S.D., et al. 2011 Compendium of physical activities: a second update of codes and MET values. Med Sci Sports Exerc 2011, 43:1575-1581.
28. Martins C., Morgan L.M., Bloom S.R., et al. Effects of exercise on gut peptides, energy intake and appetite. JEndocrinol 2007, 193:251-258.
29. Ryskjaer J., Deacon C.F., Carr R.D., et al. Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake. Eur J Endocrinol 2006, 155:485-493.
30. Adam T.C., Westerterp-Plantenga M.S. Activity-induced GLP-1 release in lean and obese subjects. Physiol Behav 2004, 83:459-466.
31. Ellingsgaard H., Hauselmann I., Schuler B., et al. Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat Med 2011, 17:1481-1489.
32. Cuthbertson J., Patterson S., O'Harte F.P., et al. Investigation of the effect of oral metformin on dipeptidylpeptidase-4 (DPP-4) activity in type 2 diabetes. Diabet Med 2009, 26:649-654.
33. Green B.D., Irwin N., Duffy N.A., et al. Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1. Eur J Pharmacol 2006, 547:192-199.
34. Lindsay J.R., Duffy N.A., McKillop A.M., et al. Inhibition of dipeptidyl peptidase IV activity by oral metformin in type 2 diabetes. Diabet Med 2005, 22:654-657.
35. Hinke S.A., Kuhn-Wache K., Hoffmann T., et al. Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1. Biochem Biophys Res Commun 2002, 291:1302-1308.
36. Maida A., Lamont B.J., Cao X., et al. Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-alpha in mice. Diabetologia 2011, 54:339-349.
37. Migoya E.M., Bergeron R., Miller J.L., et al. Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1. Clin Pharmacol Ther 2010, 88:801-808.
38. Mannucci E., Ognibene A., Cremasco F., et al. Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects. Diabetes Care 2001, 24:489-494.
39. Mannucci E., Tesi F., Bardini G., et al. Effects of metformin on glucagon-like peptide-1 levels in obese patients with and without type 2 diabetes. Diabetes Nutr Metab 2004, 17:336-342.
40. Vollmer K., Holst J.J., Baller B., et al. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes 2008, 57:678-687.
41. Salehi M., Aulinger B., Prigeon R.L., et al. Effect of endogenous GLP-1 on insulin secretion in type 2 diabetes. Diabetes 2010, 59:1330-1337.